A pilot trial of pentoxifylline in nonalcoholic steatohepatitis

American Journal of Gastroenterology

Volumn 99, Issue 12, 2004, Pages 2365-2368

  Adams, Leon A ^a   Zein, Claudia O ^a   Angulo, Paul ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; LIVER ENZYME; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HUMAN; INSOMNIA; INSULIN RESISTANCE; LEG CRAMP; LIVER BIOPSY; LIVER FIBROSIS; LIVER INJURY; MALE; NAUSEA; NONALCOHOLIC FATTY LIVER; OBESITY; PATIENT MONITORING; PILOT STUDY; PRIORITY JOURNAL; RASH; STATISTICAL SIGNIFICANCE; SWEATING;

CHI-SQUARE DISTRIBUTION; ENZYME INHIBITORS; FATTY LIVER; FEMALE; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PENTOXIFYLLINE; PILOT PROJECTS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 11144249271     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.40064.x     Document Type: Article

References (23)

1. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 1990;12:1106-10.
2. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-24.
3. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-19.
4. Charlton M, Kasparova P, Weston S, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001;7:608-14.
5. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-76.
6. Warne JP. Tumour necrosis factor alpha: A key regulator of adipose tissue mass. J Endocrinol 2003;177:351-5.
7. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-5.
8. Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001;48:206-11.
9. Neuner P, Klosner G, Schauer E, et al. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 1994;83:262-7.
10. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-48.
11. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
12. Trental (pentoxifylline) Prescribing information. Aventis Pharmaceuticals, 2003.
13. Nenci GG, Gresele P, Agnelli G, et al. Effect of pentoxifylline on platelet aggregation. Pharmatherapeutica 1981;2:532-8.
14. Yee SB, Ganey PE, Roth RA. The role of Kupffer cells and TNF-alpha in monocrotaline and bacterial lipopolysaccharide-induced liver injury. Toxicol Sci 2003;71:124-32.
15. Hung KY, Huang JW, Chen CT, et al. Pentoxifylline modulates intracellular signalling of TGF-beta in cultured human peritoneal mesothelial cells: Implications for prevention of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2003;18:670-6.
16. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997;94:2557-62.
17. Lauterbach R, Pawlik D, Kowalczyk D, et al. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: A placebo-controlled, double-blind trial. Crit Care Med 1999;27:807-14.
18. Sliwa K, Woodiwiss A, Candy G, et al. Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 2002;90:1118-22.
19. Delanian S, Porcher R, Balla-Mekias S, et al. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol 2003;21:2545-50.
20. Valenti L, Fracanzani AL, Dongiovanni P, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002;122:274-80.
21. Windmeier C, Gressner AM. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 1997;29:181-96.
22. Fang CC, Yen CJ, Chen YM, et al. Pentoxifylline inhibits human peritoneal mesothelial cell growth and collagen synthesis: Effects on TGF-beta. Kidney Int 2000;57:2626-33.
23. Falanga V, Fujitani RM, Diaz C, et al. Systemic treatment of venous leg ulcers with high doses of pentoxifylline: Efficacy in a randomized, placebo-controlled trial. Wound Repair Regen 1999;7:208-13.